The epidermal growth factor receptor (EGFR), a long-standing drug development target, is also a desirable target for imaging. 2
Introduction
Protein tyrosine kinases (PTKs), enzymes that phosphorylate tyrosine residues on functional proteins, are common mediators of signals that regulate many cellular processes. PTKs can be divided into two subgroups based on their structural characteristics, nonreceptor cytoplasmic PTKs and receptor tyrosine kinases (RTKs). 1 To date at least 20 families of receptor tyrosine kinases that share structural, most notably an intrinsic tyrosine kinase domain, and functional similarities have been classified. 2, 3 The epidermal growth factor receptor (EGFR) was one of the first oncogenes and receptor tyrosine kinases to be discovered. 4 ,5 EGFR belongs to the ErbB family of receptors, which also includes ErbB2 (HER2/Neu), ErbB3 and ErbB4. These receptors are overexpressed in a variety of tumors.
EGFR tyrosine kinase phosphorylation is stimulated by epidermal growth factor (EGF) or transforming growth factor α (TGFα) binding to the extracellular ligand binding domain of the EGFR and subsequent receptor dimerization. Signal transduction initiated by these events regulates cellular proliferation, differentiation, motility, adhesion and apoptosis. These signaling processes play an important role in normal epithelial and stromal cell morphology; moreover, overexpression or aberrant signaling from EGFR and the other ErbB receptor family members has been shown to be a key determinant in tumor growth and proliferation.
6,7
Overexpression of EGFR has been found in head and neck tumors, gliomas, non-small cell lung carcinoma and tumors of the breast, ovaries, cervix, esophagus, bladder, prostate, and kidney. 7 There is extensive literature on the clinical significance of increased EGFR expression and signaling in tumors and the relationship to other prognostic factors. 8, 9 In a majority of tumors poor survival rates correlate with EGFR overexpression. For example, EGFR overexpression has been detected in nearly 45 percent of the breast tumors studied 10 and receptor overexpression is inversely correlated with patient survival.
9
EGFR overexpression is also inversely correlated with estrogen receptor status, consistent with the failure of EGFR positive patients to respond to hormonal therapies. 11, 12 The relevance of EGFR expression in tumors to prognostic outcome supports the years of investment towards finding an EGFRtargeted therapeutic [13] [14] [15] [16] [17] [18] and the need for a diagnostic imaging agent. Development of an imaging agent might also be a valuable tool in the search for and the characterization of EGFR-targeted therapeutics.
Two potential targets for EGFR-based probes are the extracellular domain or the intracellular tyrosine kinase domain. Radioactive probes that bind to the extracellular domain of EGFR have been generated. EGF, the 53 amino acid, 6 kDa, natural ligand, binds to the EGFR with a K d of 0.1-1.0 nM 19 and has been labeled directly with iodine-123, iodine-125 and iodine-131. In vitro studies using
[ 131 I]EGF demonstrated its cytotoxic potential. 20 123 I-EGF has been used to image cervical cancer in humans. 21 In spite of its ability to localize in EGFR rich tissue, radioiodinated EGF rapidly degrades in vivo releasing radioiodine thereby reducing the lifetime of the label in the tumor. 22 Iodinated dextran-EGF conjugates increase retention of the iodine by tumor cells but at the cost of higher molecular weight that affects tracer distribution. 20 EGF has been labeled with technetium-99m using a MAG3 or 2-iminothiolane chelate and was found to accumulate in tumor xenografts with more rapid clearance than labeled monoclonal antibodies (Mabs). [23] [24] [25] Bifunctional chelation of indium-111 to EGF using diethylenetriaminepentaacetic acid (DTPA) has been shown to have cytotoxic effects in vitro and is being investigated as a potential radiotherapeutic agent. 26, 27 The imaging potential of 111 In-EGF was found to be inferior to a labeled anti-EGFR antibody, 111 In-DTPA-MAb 528 in tumor bearing rats. 28 Several MAbs against EGFR have been developed as anti-tumor agents. The radioiodinated Mab, EGFR1, with high affinity for the EGFR has demonstrated good uptake in MCF-7 tumors grown in nude athymic mice 29 and good localization in human brain gliomas. 30 Likewise, the indium-111
labeled C225 Mab has been tested in patients with squamous cell lung carcinoma. 31 A direct-labeled technetium-99m anti-EGFR antibody, ior egfr/r3, has demonstrated imaging sensitivity (84%), specificity (100%) and accuracy (86.5%) in human epithelial tumors. 32 However, MAbs labeled with short-lived PET isotopes, in general, have demonstrated limited targeting success in large part due to pharmacokinetic constraints related mostly to their size.
To date no small organic molecules with affinity for the extracellular domain of the EGFR have been identified; however, a number of small molecules have been shown to be potent (nM to pM)
inhibitors of the intracellular EGFR tyrosine kinase at the ATP binding site. A sampling of the different compound classes that inhibit EGFR phosphorylation is shown in Figure 1 . The dialkoxy-4 anilinoquinazolines ( Figure 1 ) were chosen as the lead compounds in the present study based on the strong structure-activity data. [33] [34] [35] The development of imaging agents based on the small molecule EGFR inhibitors has been a recent area of active research. A number of radiolabeled anilinoquinazoline analogs have been reported.
The compounds incorporate labeled substituents on the A or C rings (see Figure 1) receptor-mediated uptake, based on blocking studies, observed for the latter probe. Low receptor affinity, high non-specific binding and probe metabolism may have contributed to the inability of these compounds to accumulate in tumor cells that overexpress EGFR.
Successful development of an imaging probe targeting a new biomarker, in this case EGFR, requires an adequate screening strategy for the selection of ligands to be carried forward for labeling and, ultimately, in vivo studies. It is neither economically nor logistically feasible to label and evaluate every compound in animal models. Likewise, navigating the structure activity relationships in the medicinal chemistry literature can be challenging with respect to choosing an appropriate imaging lead compound. For example, the fact that a small molecule is a potent EGFR inhibitor does not necessarily guarantee that it will possess desirable EGFR imaging characteristics such as high receptor affinity, high receptor selectivity, low non-specific binding, rapid clearance and suitable metabolism.
In the current study, a small series of dialkoxyquinazoline EGFR inhibitors suitable for labeling with fluorine-18 (110 min half-life positron-emitter) or carbon-11 (20 min half-life positron-emitter) has been synthesized. Appropriate assays have been developed to determine both functional and imaging characteristics, including a new radiometric binding assay to measure the affinity of the inhibitors for the enzyme. These studies provide the basis needed for the selection of ligands to be labeled and further evaluated as potential imaging agents for the non-invasive determination of EGF receptor density.
Results

Chemistry.
A small library of anilino-and benzyl-dialkoxyquinazoline compounds 10-17 were prepared by coupling 4-chloro-dialkoxyquinazoline 8 or 9 with the appropriate substituted aniline or benzylamine (Scheme 3). The 4-chloro-6,7-dimethoxyquinazoline was synthesized as previously reported from the 4,5-dimethoxyanthranilic acid 5. 33 As the 4-(3´-bromoanilino)-6,7-diethoxyquinazoline was reported 33 to possess more potent biological activity than the corresponding 6,7-dimethoxy analog, we were interested in finding a convergent synthetic route suitable for the preparation of several diethoxy analogs. The previously reported two step conversion of the dimethoxy-bromoanilinoquinazoline 11c to the diethoxy analog 10c (Scheme 3), using a pyridinium hydrochloride melt to give the bishydroxy intermediate followed by O-alkylation with iodoethane, proceeded in a low 5.5% yield. 33 This was inadequate for the preparation of a series of the diethoxy analogs. Thus, we produced the 4,5-diethoxyanthranilic acid 4 by two methods (Scheme 1). Initially, a small amount of methyl 2-amino-4,5-diethoxybenzoate 3 was commercially available from Aldrich Specialty Chemical. The benzoate 3 was directly converted to 4 by saponification of the methyl ester. Alternatively, when the commercial supply was depleted, 4,5-diethoxybenzoic acid 1 was nitrated to give 2 followed by reduction of the nitro group to form the desired amino-benzoic acid 4 in moderate overall yield.
Preparation of the 4-chloroquinazolines followed a previously described procedure (Scheme 2).
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Cyclization of the dialkoxyanthranilic acids, 4 or 5, with formamidine hydrochloride at 210˚C gave the corresponding dialkoxyquinazolinones, 6 or 7, in 55-65% yield. The quinazolinones were subsequently refluxed with oxalyl chloride in DMF and 1,2-dichloroethane to form the 4-chloro-dialkoxyquinazolines 8 and 9 in good yield.
A modified coupling procedure was employed for the production of the anilino-and benzylaminoquinazolines (Scheme 3). Anhydrous DMF was used as the reaction solvent instead of the previously reported isopropanol. The reaction was carried out at 80˚C with nearly quantitative conversion to the substituted aminoquinazoline hydrochloride (HCl) salt within 30 min to 1 h depending on the aniline substituents. The precipitated HCl salt was filtered from the DMF solution and was converted to the free base for semi-preparative normal phase HPLC purification. The pure quinazolines were reconverted to the more stable HCl salt for the biological assays.
Chemical and physical data for all of the compounds is presented in Table 1 . All of the anilino-and benzyl-quinazoline analogs were analyzed by analytical reversed-phase HPLC and found to be greater than 99% pure. Elemental analysis of all of the dialkoxyquinazoline analogs in Table 1 agree with the calculated values to within ±0.4%
Lipophilicity measurement.
The lipophilicity of compounds can affect their tissue permeability properties that can impact their localization in target tissues. Lipophilicity may also affect binding to low affinity nonspecific sites that can compromise target tissue to background tissue ratios. The octanol/water partition coefficients of the quinazoline compounds were estimated by a reversed-phase HPLC method. 44 This method has been previously used by us to determine lipophilicities of steroid ligands. 45 The estimated Log P o/w values are reported in Table 1 Biological Activity.
The sixteen quinazoline compounds were studied in a battery of in vitro assays to assess their biological properties and to develop a basis for screening these and future compounds for potential imaging agents. A radiometric binding assay was developed to determine the relative binding affinities of these compounds for the ATP binding site in the tyrosine kinase domain of the receptor. The ability of these molecules to inhibit EGFR tyrosine phosphorylation was probed. The specificity of a small subset of compounds was determined by assessing inhibition of ErbB2 and ErbB4 receptor phosphorylation. Finally, the ability of the ligand to inhibit cellular DNA synthesis, in cells dependent and not dependent on EGF for cell proliferation, was evaluated. This assay was performed in an effort to find a test that would be amenable to high throughput screening and whose results would potentially correlate with receptor binding and ultimately with the pharmacokinetic distribution of the tracer in vivo.
Receptor binding is a key characteristic that these molecules must possess to be suitable imaging agents. A receptor binding assay using EGF receptors extracted from the A431 human carcinoma cell membranes was developed and used to study the relative binding affinity of these compounds to the tyrosine kinase domain. Iodine-125 labeled 11d (specific activity 583-596 Ci/mmol) was employed as the radioligand 36 and non-specific binding was determined by adding 11c, the bromo-analog, to the assay. EGFR binding values, expressed as an IC 50 , are shown in Table 2 . All of the compounds demonstrated high affinity for the receptor with IC 50 s ranging from 0.4 -51 nM. In all cases the diethoxy analogs had relatively higher affinity for the receptor than the corresponding dimethoxy derivatives. Analogs 10b-10d and 11b-11d, the meta-chloro-, bromo-and iodo-anilino analogs, exhibited the highest relative affinities (nanomolar to subnanomolar) for the tyrosine kinase domain.
Three fluoroanilino analogs, 10a, 12, and 16a displayed relative affinities slightly less than 10 nM, generally considered the upper limit for imaging agents 46, 47 , while the remaining analogs had relative affinities greater than 16 nM. Specificity for the EGF receptor versus other receptor tyrosine kinases, especially ErbB2 and ErbB4, is another desirable imaging characteristic. Thus, a small set of compounds was evaluated for inhibition of ligand-induced ErbB2 and ErbB4 tyrosine phosphorylation (kinase activity). The specificity of the compounds tested for EGFR appears to be high (Table 2) . For the four compounds tested (10c, 10d, 11c, and 14), the ErbB2 and ErbB4 tyrosine phosphorylation (kinase) IC 50 values were at least one order of magnitude greater than the EGFR tyrosine phosphorylation (kinase) IC 50 values. We do recognize that this is a comparison of phosphorylation inhibition rather than binding.
The specificity of the molecules for EGFR was also determined by examining their effect on DNA synthesis by the EGF-dependent MCF-10A human mammary epithelial cell line and the EGFindependent MCF-7 human mammary tumor cell line. These cell lines were treated with various concentrations of several of the compounds and DNA synthesis was measured by assaying 3 H-thymidine incorporation. These data were used to calculate the DNA synthesis IC 50 values for each compound in the two cell lines, shown in Table 3 . The MCF7 DNA synthesis IC 50 values for the compounds were at least one order of magnitude higher than the corresponding MCF10A DNA synthesis IC 50 values.
Because the DNA synthesis of MCF10A cells is EGF-dependent, these data suggest that the compounds inhibit MCF10A DNA synthesis by inhibiting the EGFR rather than some other target.
Discussion
There are four well-established criteria for the development of disease-specific radioprobes that would be sensitive to changes in binding site concentration. 46, 47 They are: i) identify a binding site whose concentration changes as a function of a specific disease; ii) design and produce a radioprobe that selectively targets the binding site; iii) evaluate sensitivity as a function of altered binding site concentration; and iv) evaluate sensitivity relative to the selected disease. The EGF receptor overexpression in various tumors satisfies the first criterion. Identifying lead molecules to test as imaging probes and developing an underlying selection process to identify future candidate molecules, the subject of the present effort, begins to address the second criterion.
Designing and producing an enzyme-or receptor-binding radioprobe involves several steps, often an iterative process, intended to obtain a thorough understanding of the biochemical and physiological behavior of the probe to match against a set of desirable imaging characteristics. 46, 47 A receptor-binding radiotracer should meet the following criteria: i) high affinity for the desired enzyme or receptor, typically <10 nM; ii) appropriate lipophilicity (coupled to cell membrane or blood-brain barrier penetration, typically 1.5 -3.0); iii) high selectivity for the enzyme or receptor (e.g. low affinity
for receptors within the same family or similar proteins, typically >10:1); iv) suitable metabolic properties (labeled metabolites can alter the distribution profile of the probe); and v) rapid clearance from non-target tissues and the body (necessary for good target-to-background ratio, typically >3:1 and lower radiation dose to the subject). In vitro data for a series of dialkoxyquinazoline EGFR-targeted compounds have been gathered and used to select probes for labeling and in vivo evaluation. These data were used to establish a ligand selection process. The process is detailed in the context of the following discussion.
The dialkoxyquinazolines ( Figure 1 ) were chosen as the lead compounds in the present study based on the reported structure inhibition relationships. [33] [34] [35] Fry and colleagues demonstrated that the quinazoline backbone and the 6,7-dimethoxy moieties were necessary for enhanced EGFR tyrosine kinase inhibition. The 6,7-diethoxy analog 10c exhibited a four-fold lower inhibition IC 50 value (6 pM vs 25 pM) and halogen substitution at the 2´, 3´, 4´ and 5´ positions, even 3´, 4´ dibromination, of the anilino ring ("C" ring Figure 1 ) was well tolerated. The fluorobenzylamino analog was not previously studied but based on the radiochemical availability of this analog it was included here. 48 The unsubstituted benzyl compound was evaluated as an inhibitor and found to have a 3 fold lower inhibition IC 50 value (10 nM) compared to the corresponding unsubstituted anilino compound (29 nM). 33, 35 The 3-fluoro-5-trifluoromethylaniline as well as 2-, 3-and 4-fluoroaniline can be synthesized with fluorine-18 so the corresponding non-radioactive analogs were added to the study. 49 Inhibition data from the 4-(3'-trifluoromethylanilino)-6,7-dimethoxyquinazoline (inhibition IC 50 = 0.24 nM) and the 3'-fluoroanilino analog (inhibition IC 50 = 3.8 nM) supported their inclusion.
The preparation of the analogs for this study was straightforward. The 4-chloro-dimethoxy-or diethoxy-quinazoline intermediates were synthesized and coupled with the appropriate aniline or benzylamine to yield the desired anilino-or benzylamino-quinazolines in good yield. The approach outlined herein improved upon the chemistry previously described by Bridges et al. 33 and provides a suitable starting point to generate libraries of anilino-or benzylamino-quinazolines with any dialkoxy or mixed alkoxy substituents in the 6 and 7 positions. In cases where facilitated transport is nonexistent cell membrane permeability is a direct function of the diffusion coefficient and compound lipophilicity. If the partition coefficient value is too low, the compound will not cross a cell membrane; if the value is too high, hydrophobic interactions with lipids and proteins will dominate, leading to high non-specific binding, compromising image contrast. It has been demonstrated for radiotracers crossing the blood-brain barrier that a Log P o/w range of 1.5 -3 is optimal. 56 While this range works equally well for non-brain receptor-targeted tracers, estrogen radioprobes with higher lipophilicity (up to Log P = 4.5) have been successful tumor imaging agents. 57 Therefore, the Log P o/w range for the selection of the EGFR probes in the current study has been set from 1.5 to 4. The HPLC derived lipophilicities (Log P o/w ) ranged from 2.2 to 5.5. Of those compounds previously chosen, 10a and 11b-d and 16a fall within this desired range.
Selectivity for the chosen receptor is the final in vitro test. One preliminary measure of receptor selectivity that was employed in this study was to evaluate ErbB2 and ErbB4 inhibition. All of the compounds were much less potent inhibitors of ligand-induced ErbB2 and ErbB4 phosphorylation than of ligand-induced EGFR phosphorylation. Indeed the compounds tested here exhibit between one and two orders of magnitude of selectivity for the EGFR over ErbB2 or ErbB4. All of the compounds tested may be reasonable EGFR-selective tumor imaging agents. The optimal agent would exhibit the least amount of avidity for other RTKs. In many types of tumor cells ErbB2 is frequently overexpressed at levels comparable to the levels of EGFR overexpression. 7 Similarly, ErbB4 is expressed in the normal mammary epithelium 59 and infrequently overexpressed in tumor tissue. 58, 59 These observations highlight the need for EGFR-selective imaging agents that exhibit minimal binding to ErbB2 and ErbB4, among other RTKs, in order to determine and understand EGFR expression using molecular imaging techniques.
The quinazoline compounds were also assayed for inhibition of cellular DNA synthesis in EGFdependent (MCF10A) and EGF-independent (MCF7) cell lines. This assay, like the inhibition of ligand-induced receptor tyrosine phosphorylation assays, not only assesses the specificity of a compound for EGFR, but also provides a measure of a compounds ability to penetrate cells and specifically target the EGFR. Thus, it is not surprising that compound 12, which we hypothesized failed to inhibit ligand-induced EGFR tyrosine phosphorylation because it exhibits limited cell penetration, also failed to inhibit EGF-dependent and -independent DNA synthesis.
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A modified literature procedure 33 was developed to produce 6. A 500 mL round bottom flask equipped with an air condenser was charged with 2-amino-4,5- Dilute NaOH (0.33N, 20 mL) was added to the flask. The mixture was sonicated at room temperature for 1 hour producing in a dark gray-purple suspension. 
4-chloro-6,7-diethoxyquinazoline (8).
Following a modified literature procedure 33 , DMF (0.94 mL, 12.1 mmol) was added dropwise to a solution of 1,2-dichloroethane (8.1 mL) and oxalyl chloride (1.1 mL, 12.6 mmol) stirring under argon, vigorously releasing gas. Following cessation of the gas production, 6,7-diethoxyquinazolin-4-one 6 (1.89 g, 8.1 mmol) was added to the thick white slurry then refluxed for 2.5 hours, resulting in a yellow-brown suspension. The reaction was quenched by addition of Na 2 HPO 4 (0.5M, 16.8 mL) followed by stirring in an ice bath for 1 hour. The suspension was filtered and washed with water (200 mL) to isolate 4-chloro-6,7-diethyoxyquinazoline 8 as a pale gray solid, 4-chloro-6,7-dimethoxyquinazoline (9). 6,7-dimethoxyquinazolin-4-one 7 (3.40 g, 16.5 mmol) was converted to 9 in 52% yield ( 
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4-(3´-fluoroanilino)-6,7-dimethoxyquinazoline hydrochloride (11a).
Similar treatment of 9 (0.032g, 0.14 mmol) with 3-fluoroaniline yielded 11a (27% 
4-(3´-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride (11b).
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The log k' w was determined by linear extrapolation of the compound residence time (retention volume less void volume) versus the methanol concentration over a range of 60 to 85% methanol mobile phase.
Biological Methods.
Cell Lines and Cell Culture. The CEM human T lymphocyte cell line engineered to express ErbB4
(CEM/4) and its culture conditions have been described previously. 51, 52 Briefly, these cells were propagated in RPMI supplemented with 10% heat-inactivated fetal bovine serum and 300 μg/ml G418.
The BaF3 mouse lymphoid cell lines engineered to express either EGFR (BaF3/EGFR) or ErbB2 and ErbB3 together (BaF3/2+3) and the culture conditions for these cell lines have been described earlier. 53 Briefly, these cells were propagated in RPMI supplemented with 10% fetal bovine serum, 300 μg/ml G418, and 10% medium conditioned by WeHI cells. This conditioned medium serves as a source for This enabled us to determine the concentration of a given tyrosine kinase inhibitor that was necessary to cause a 50% reduction in receptor tyrosine phosphorylation. This value is reported as the receptor tyrosine phosphorylation IC 50 value.
Inhibition of Cellular DNA Synthesis. The assay for inhibition of cellular DNA synthesis was adapted from a previously-described protocol. 54 Briefly, human mammary (tumor) cells were seeded in 1 mL aliquots into 24-well culture dishes at a density of 10 5 cells/well. Cells were incubated for 24 hours at 37 o C, and a tyrosine kinase inhibitor dissolved in DMSO was added to each well in a volume of 10 μL.
Each tyrosine kinase inhibitor was assayed at 3-5 different concentrations and each concentration was assayed using 3-4 wells of cells. Cells treated with 10 μl DMSO served as the solvent control. Cells were then incubated for 48 hours at 37 o C. homogenized with a hand held homogenizer. This preparation was added to the buffer solution followed by the addition of 1 μCi of the radiotracer to initiate the binding assay. The mixture was incubated at room temperature in the dark for 60 min. The incubation was terminated by the addition of 5 mL of ice cold buffer (10 mM HEPES, 1 mM EDTA, 5 mM MgCl 2 , and 0.1% BSA (pH 7.4)) and the solutions were filtered through polyethylenamine soaked (0.5% soln., 30 min) GF/B filter paper (Brandel, Gaithersburg, MD) using a Brandel Cell Harvester, followed by two washes (5 mL each) with wash buffer. The filter paper was dried and counted for 10 minutes using a TM Analytic gamma well counter.
Non-specific binding was determined by adding 1 μM 4-(3′-bromoanilino)-dimethoxy quinazoline to the assay. Inhibition constants at 50% of specific binding (IC 50 ) were derived from specific binding versus concentration curves. Triplicate assays were performed for each compound.
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